Emerging Growth Capital Investors offers retail and wholesale investors access to a fund of Australian small cap listed biotechnology and life science companies.
QIC is gearing up to expand its hedge fund allocation as – together with insurance exposure – the “strong double-digit return” of its liquid alternatives portfolio was a key contributor to the fund’s record $8.9 billion earnings in the 2024 financial year. Chief investment officer Allison Hill explains why global sovereign wealth funds are hot on hedge funds.
Darcy SongOctober 24, 2024
